Press Releases

April 29, 2025 - Advicenne 2024 Universal Registration Document made available

March 27, 2025 - Advicenne: Fiscal year 2024 marked by the satisfactory commercial performance of Sibnayal® in Europe and development in the United States

January 29, 2025 - Advicenne reaches a significant milestone with the US FDA in the development of ADV7103 in cystinuria

January 23, 2025 - Advicenne announces 2024 gross sales

December 19, 2024 - Advicenne finalizes agreement with Primex Pharmaceuticals AG

November 28, 2024 - Advicenne announces its 2025 financial calendar

October 1, 2024 - Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103

September 18, 2024 - Advicenne reports its First Half financial results as of June 30, 2024, and updates on its activities

July 18, 2024 - Advicenne announces an 8.8% increase in gross sales for H1 2024 and provides an update on its activities

May 15, 2024 - Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

April 5, 2024 - Advicenne 2023 Universal Registration Document made available

March 28, 2024 - Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal®

March 25, 2024 - FDA grants Orphan Drug Designation to ADV7103 for the treatment of cystinuria

January 23, 2024 - Advicenne reports 2023 gross sales up 20% to €4.43 million

December 28, 2023 - Advicenne announces its 2024 financial calendar

October 2, 2023 - Advicenne announces the results of its capital increase with preferential subscription rights

September 25, 2023 - Advicenne announces its participation in several scientific conferences and the presentation of updated clinical results about ADV7103

September 11, 2023 - Advicenne reports its First Half Financial results as of June 30, 2023 and updates on its activities

July 12, 2023 - Advicenne announces 51% growth in Sibnayal® gross sales in H1 2023 to almost €1.0 million

June 14, 2023 - Advicenne announces long-term results of the European clinical development program for ADV7103

June 9, 2023 - Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

May 19, 2023 - Advicenne annual combined general meeting of June 8, 2023 – Availability of preparatory documents

April 28, 2023 - Advicenne 2022 Universal Registration Document made available

March 30, 2023 - Advicenne reports its financial results for the year ended December 31, 2022

March 6, 2023 - Advicenne announces the launch of Sibnayal® in Denmark

February 28, 2023 - Advicenne completes European commercial coverage of Sibnayal® through its agreement with Avanzanite Bioscience

February 14, 2023 - Advicenne and SPA announce an exclusive distribution agreement for the marketing of Sibnayal® in Italy, Spain and Portugal

February 1, 2023 - Advicenne provides an update on its commercial partnerships in Europe and the Middle East

January 24, 2023 - Advicenne reports 2022 sales up 13% to €3.7 million

December 13, 2022 - Advicenne obtains Orphan Drug Designation for ADV7103 in the United States for the treatment of distal Renal Tubular Acidosis (dRTA)

December 5, 2022 - Advicenne announces the second tranche drawdown of its non-dilutive financing agreement with the EIB

November 30, 2022 - Advicenne announces its financial calendar for 2023

November 3, 2022 - Advicenne announces its upcoming participation in two of the most important international investor conferences

October 5, 2022 - Advicenne announces the extension of the intellectual property of its drug Sibnayal®

September 21, 2022 - Advicenne reports its First Half Financial results as of June 30, 2022

September 14, 2022 - Advicenne updates on availability of Sibnayal® to patients and caregivers in Great Britain

June 30, 2022 - Advicenne announces commercial launch of Sibnayal® in Great Britain

June 28, 2022 - Advicenne announces commercialization agreement with Taïba Healthcare for Sibnayal® in Middle-East

June 10, 2022 - Advicenne provides an update on its activities following its Annual General Meeting and Board of Directors meeting on June 9, 2022

May 30, 2022 - Advicenne announces the launch of its new website

April 29, 2022 - Advicenne 2021 Universal Registration Document made available

April 21, 2022 - Advicenne appoints Philippe Boucheron as Chairman of its Board of Directors

April 5, 2022 - A case report highlights the interest of a long-term treatment with ADV-7103 in dRTA

March 31, 2022 - Advicenne Reports its Financial Results for the Year ended 31 December 2021

March 30, 2022 - Advicenne announces the release of results of a study showing improved quality of life in patients living with DRTa and treated by ADV7103

March 28, 2022 - Advicenne announces the transfer of its shares from Euronext Paris and Euronext Brussels to Euronext Growth Paris on March 30, 2022

January 21, 2022 - Advicenne ordinary shareholders’ meeting approved the project to transfer Advicenne’s shares listing to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

January 18, 2022 - Advicenne reports 2021 sales up 20% to €3.3 million

January 4, 2022 - Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region

December 27, 2021 - Advicenne announces its financial calendar for 2022

December 20, 2021 - Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug Sibnayal™ in dRTA

December 7, 2021 - Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

December 3, 2021 - Proposed transfer of the listing of Advicenne’s shares to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

September 29, 2021 - Advicenne Reports 2021 Half Year Financial Results

July 2, 2021 - Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

June 23, 2021 - Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons

June 22, 2021 - Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m

June 15, 2021 - Advicenne provides an update on its activities following its Annual General Meeting

June 10, 2021 - Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m

May 17, 2021 - Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)

May 3, 2021 - Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

April 28, 2021 - Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook

April 23, 2021 - 2021 Financial Calendar

March 25, 2021 - Precision on the press release dated March 19, 2021

March 19, 2021 - Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe

February 18, 2021 - Advicenne Provides an Update as its Operations Evolve

January 7, 2021 - Advicenne Announces the Appointment of Peter Meeus as Chief Executive Officer

December 10, 2020 - Advicenne receives positive CHMP opinion recommending approval of ADV7103 (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

October 27, 2020 - Advicenne obtains non-dilutive loan facility of €4.3 million guaranteed by the French State

September 25, 2020 - Advicenne Presents 2020 Half-Year Financial Report and Provides Update on Outlook and Recent Developments

August 11, 2020 - Advicenne Strengthens Its Financial Structure Through the Implementation of its €20 Million Financing Agreement with the European Investment Bank, with the Drawdown of a First Tranche of €7.5 Million

May 26, 2020 - Advicenne Shareholders Adopt All Resolutions Recommended by the Board of Directors at Its Combined Shareholders Meeting

May 25, 2020 - Advicenne Gears Up for Accelerated Growth

May 5, 2020 - Advicenne Combined Shareholders Meeting to Be Held on May 26 Behind Closed Doors

March 13, 2020 - Advicenne Reports Full-Year 2019 Financial Results and Confirms Operational Outlook for 2020

March 13, 2020 - Advicenne Announces the Appointment of André Ulmann as Interim Chief Executive Officer

March 10, 2020 - Advicenne Makes ADV7103 8 mEq and 24 mEq Prolonged-Release Granules Available Within Framework of French Temporary Authorization for Use (TAU) Scheme

January 28, 2020 - Advicenne Publishes its Financial Calendar for 2020

December 18, 2019 - Advicenne’s Lead Candidate Approved for Orphan Drug Designation in the Treatment of Cystinuria in Europe

November 15, 2019 - Advicenne intends to appoint David Horn Solomon as Chairman of the Board of Directors in line with its International Strategy

October 28, 2019 - Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

September 27, 2019 - Advicenne Publishes its 2019 Half-Year Financial Report

September 24, 2019 - Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook

September 20, 2019 - Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences

September 4, 2019 - Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck

September 3, 2019 - Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London

August 29, 2019 - Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)

July 26, 2019 - Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC

July 18, 2019 - Financial Visibility and Accelerated Development

June 13, 2019 - Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

June 12, 2019 - Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels

May 23, 2019 - Advicenne announces its intention to list on the regulated market of Euronext Brussels

April 30, 2019 - Advicenne Publishes its 2018 Annual Financial Report

April 9, 2019 - Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

March 21, 2019 - Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

March 12, 2019 - Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

January 7, 2019 - Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

December 21, 2018 - Advicenne Publishes its Financial Calendar for 2019

October 26, 2018 - Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes

October 15, 2018 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

October 4, 2018 - Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

September 25, 2018 - Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

September 20, 2018 - Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

September 12, 2018 - Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

September 5, 2018 - Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

July 2, 2018 - Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

May 31, 2018 - Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

May 15, 2018 - Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

May 4, 2018 - Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

April 30, 2018 - Advicenne publishes its annual financial report

April 18, 2018 - Advicenne 2017 Financial Results and Operational Perspectives for 2018

February 12, 2018 - Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

January 24, 2018 - Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

January 5, 2018 - Partial exercise of over – allotment option

December 5, 2017 - Success of the IPO

November 21, 2017 - Advicenne launches IPO on Euronext’s regulated market in Paris

November 6, 2017 - ADV7103: 6-month data presented at ASN

November 2, 2017 - Advicenne announces the registration of its Document De Base in relation to its planned IPO on Euronext’s regulated market in Paris

September 20, 2017 - Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis

September 11, 2017 - Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

July 2, 2017 - Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy

June 21, 2017 - Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting

March 20, 2017 - Advicenne Announces the Closing of a €16 Million Financing Round

September 1, 2016 - Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer

February 23, 2016 - Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals

April 23, 2015 - French marketing authorization approval for Levidcen

February 20, 2014 - Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules